Reactions 1704, p305 - 2 Jun 2018 Pembrolizumab/talimogene laherparepvec Nephritis, fever and chills: case report A 68-year-old man developed immune-mediated nephritis following treatment with pembrolizumab and fever and chills following treatment with talimogene laherparepvec [routes and dosages not stated]. The man had lentigo maligna melanoma of the scalp for which he was started on treatment with pembrolizumab. Following three doses of pembrolizumab, he developed grade 3 immune-mediated nephritis. The man was then treated with prolonged steroid course. Later, he was started on treatment with intratumoral talimogene laherparepvec therapy to address local disease progression in the setting of recent immune-mediated adverse events. Talimogene laherparepvec was administered according to standard dosing guidelines. He tolerated the therapy well except he developed low-grade fevers and chills after initial treatment, that resolved with acetaminophen premedication [durations of treatment to reactions onset not stated; not all outcomes stated]. Author comment: "Given concern for true progression, pembrolizumab was initiated. After 3 doses, he had grade 3 immune-mediated nephritis requiring a prolonged steroid course." "Overall, the patient tolerated [talimogene laherparepvec] well, reporting low-grade fevers and chills after initial treatment, which resolved with acetaminophen premedication." Rizzo JM, et al. Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy. JAAD Case Reports 4: 379-381, No. 4, May 2018. Available from: URL: http://doi.org/10.1016/ j.jdcr.2018.01.023 - USA 803323243 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud